7MM age-related macular degeneration market to reach $20.5b by 2034

Its growth is supported by the anticipated launch of 26 new pipeline agents.

The age-related macular degeneration (AMD) market in the seven major markets (7MM) is set to grow to $20.5b in 2034, said GlobalData.

The sector’s expansion is attributed to the entry of therapies with longer durations, new mechanisms of action, the availability of therapies for geographic atrophy (GA), and the launch of the first therapy for early AMD.  

In addition, the market’s growth will be supported by the anticipated launch of 26 new pipeline agents and the growing AMD population during the forecast period.

Meanwhile, the late-stage pipeline for GA comprises 12 therapies across the 7MM.

“These late-stage pipeline candidates are of great benefit within the AMD space,” said Sara Reci, MSc, Managing Pharma Analyst at GlobalData.

However, therapies are expected to lose market exclusivity, leading to the anticipated entry of biosimilars.

“Nonetheless, the launch of late-stage pipeline therapies with new mechanisms of action, routes of administration, longer treatment intervals, and improved efficacies will undoubtedly be a driving force for market growth in the AMD space,” Reci added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan